Quob Park Estate Ltd signed a letter of intent to acquire 70% stake in Aiomed GmbH from Biosign Technologies Inc. (TSXV:BIO) for €3.2 million on January 21, 2016. Pursuant to the letter of intent, Biosign Technologies agreed to sell the Aiomed shares in exchange for receipt of €1.36 million in shares of Quob Park Estates, €1 million repayment against the loan payable by Aiomed to Biosign on or before November 30, 2016 and loan notes of €0.87 million to Aiomed to repay a debt to the founder of Aiomed on or before August 31, 2016. In addition, Quob Park Estates has agreed to provide loans to Biosign up to €0.65 million to fund Biosign operations for the period up to the date of a special shareholder meeting required to approve the divestiture transaction.

In a related deal, Biosign Technologies Inc. (TSXV:BIO) agreed to purchase additional 36.5% stake in Aiomed GmbH from the founder in stock on January 21, 2016. If the divestiture transaction is approved by shareholders, Biosign's remaining ownership will represent 5% of the issued and outstanding shares of Aiomed. The transaction is subject to finalizing a purchase and sale agreement and obtaining regulatory and shareholder approval of Biosign Technologies. The currency has been converted from www.oanda.com as of January 21, 2016.

Quob Park Estate Ltd cancelled the acquisition of 70% stake in Aiomed GmbH from Biosign Technologies Inc. (TSXV:BIO) on April 13, 2016. Biosign Technologies was unable to secure additional Aiomed shares to complete the purchase transaction.